There is no single test that tells you whether you have HPV. The diagnosis depends on the type of HPV involved, where it is in the body, and whether you have symptoms. For visible genital warts, a healthcare provider can often diagnose HPV just by looking. For the high-risk strains that can lead to cancer, diagnosis relies on screening tests that detect the virus in cervical or anal cells before any symptoms appear.
Cervical HPV Screening by Age
Most HPV diagnoses in women happen through routine cervical cancer screening, not because of symptoms. The recommended approach changes based on your age. For women 21 to 29, screening involves a Pap smear (cervical cytology) every three years. HPV-specific testing is not recommended in this age group because HPV infections are extremely common in younger women and almost always clear on their own.
Starting at age 30, you have three options: a Pap smear alone every three years, a high-risk HPV test alone every five years, or both tests together (called co-testing) every five years. The HPV test looks for 13 or 14 high-risk strains most likely to cause cervical cancer. Screening is not recommended before age 21 or after age 65 for women who have had adequate prior screening and are not at high risk.
What HPV Tests Actually Detect
The two main types of HPV tests work differently. DNA tests look for the genetic material of the virus itself. They are highly sensitive, catching about 96 to 98% of significant cervical abnormalities, but they can also pick up infections that are transient and would never cause problems. The most widely used versions screen for a panel of high-risk strains all at once, with separate identification of HPV 16 and 18 because these two types carry the highest cancer risk.
mRNA tests take a different approach. Instead of simply detecting whether the virus is present, they look for signs that the virus is actively producing the proteins that drive cells toward cancer. This makes them more specific, meaning fewer false alarms, but they can miss infections that haven’t yet ramped up that activity. In clinical studies, mRNA-based tests had a specificity around 97% compared to about 92% for DNA tests, but their sensitivity was lower at roughly 64%. In practice, your provider will choose the test that fits your clinical situation. You won’t typically need to request a specific type.
What Happens After an Abnormal Result
A positive HPV test doesn’t mean you have cancer or even precancer. It means a high-risk strain was found, and further evaluation may be needed depending on which strain and what your Pap results show. If HPV 16 or 18 is detected, a colposcopy with biopsy is recommended even if your Pap smear looks normal, because these strains carry the highest risk of progressing to serious cell changes.
During a colposcopy, a provider uses a magnifying instrument to closely examine the cervix. A dilute vinegar solution is applied to the tissue, which causes abnormal areas to turn white and become visible. If anything looks concerning, a small tissue sample is taken for biopsy. The biopsy result determines whether you need treatment, closer monitoring, or can return to routine screening. The entire decision is based on your estimated risk of having or developing significant precancerous changes, factoring in both your current results and your screening history.
Diagnosing Visible Genital Warts
Genital warts caused by low-risk HPV types (most commonly strains 6 and 11) are diagnosed visually. A healthcare provider can identify them by their appearance alone in most cases. When warts are flat or hard to see, a provider may apply a vinegar solution to the skin, which turns HPV-affected areas white and makes them easier to spot. No blood test, swab, or lab work is needed for a straightforward case of visible warts. A biopsy is only done if the appearance is unusual or if there’s concern about a different skin condition.
HPV Diagnosis in Men
There is no FDA-approved HPV test for routine screening in men. No blood test, urine test, or swab can tell a man his “HPV status.” For men, diagnosis is limited to visual inspection of genital warts or, in certain high-risk groups, anal screening.
Men who are at elevated risk for anal cancer, including men who have sex with men and people living with HIV, may be offered anal cancer screening. This uses the same basic approach as cervical screening: an anal Pap smear collects cells from the anal canal, which are examined for abnormalities. High-risk HPV testing can also be performed on anal samples. If results are abnormal, the next step is high-resolution anoscopy, which is essentially a colposcopy for the anal canal, allowing the provider to identify and biopsy suspicious areas. A digital rectal exam is recommended at every screening visit to check for masses that screening tests might miss.
Oral and Throat HPV
There is currently no approved test to screen for HPV in the mouth or throat. Oropharyngeal cancers linked to HPV are typically discovered when a person develops symptoms like a persistent sore throat, difficulty swallowing, or a lump in the neck, and a biopsy confirms HPV involvement. There is no routine screening program for oral HPV, even for people at higher risk.
Self-Collection Options
In 2024, the FDA expanded approval for two HPV tests, Onclarity and cobas HPV, to allow self-collection of vaginal samples. If you’re uncomfortable with a pelvic exam or can’t have one, you can now swab yourself using a brush or swab provided at a healthcare setting. The key limitation: this must currently be done in a clinical location like a doctor’s office, pharmacy, or mobile clinic. It cannot yet be done at home, though a large clinical trial called SHIP is underway with the goal of eventually extending approval to true at-home collection.
Self-collection is a significant step for people who have been avoiding cervical cancer screening due to discomfort, anxiety, or access barriers. The test performed on self-collected samples is the same high-risk HPV test used on clinician-collected samples.
Limits of HPV Testing
No test is perfect. In one well-known clinical trial, 33 out of 621 women diagnosed with advanced precancerous changes initially tested negative for high-risk HPV. When researchers investigated, only 8 of those 33 cases were true false negatives from the test itself. The rest were explained by new infections acquired after the test, biopsy results that were later downgraded, or infections caused by lower-risk HPV types unlikely to progress. This means the real-world false-negative rate for HPV testing in serious precancer is quite low, but it reinforces why repeat screening at regular intervals matters. A single negative test is reassuring but not a lifetime guarantee.
HPV tests also cannot tell you when you were infected or who transmitted the virus. A positive result reflects current infection, not the timing or source. Because HPV can remain dormant for years, a new positive test does not necessarily mean a new exposure.